18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy
Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT. 18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2010, 77: 1420-1425. PMID: 20056345, DOI: 10.1016/j.ijrobp.2009.06.049.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCA-19-9 AntigenDeoxycytidineDisease-Free SurvivalFluorodeoxyglucose F18GemcitabineHumansMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPositron-Emission TomographyRadiopharmaceuticalsRadiosurgeryRadiotherapy DosageRetrospective StudiesConceptsMetabolic tumor burdenStereotactic body radiotherapyPancreas cancer patientsPositron emission tomographyMedian survivalCancer patientsOverall survivalMultivariate analysisHigh metabolic tumor burdenMaximum standardized uptake valueAdvanced pancreas cancerProgression-free survivalGemcitabine-based chemotherapyLength of survivalStandardized uptake valuePET scan parametersProgression-FreeChemotherapy cyclesHigher SUVmaxIndependent predictorsTumor burdenBody radiotherapyPancreas cancerPrognostic valueMedian SUVmax